New England Journal of Medicine· 2019Q1
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
- 945citations
- Q1SCImago
- 2019year
Short summary
Adding gemcitabine and cisplatin induction chemotherapy to standard chemoradiotherapy significantly improved 3-year recurrence-free survival (85.3% vs. 76.5%) and overall survival (94.6% vs. 90.3%) in patients with locoregionally advanced nasopharyngeal carcinoma.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Otorhinolaryngology
OtorhinolaryngologyMedicine